Related Experiment Videos
Biology and therapy of childhood acute nonlymphocytic leukemia
D K Kalwinsky1, J Mirro, G V Dahl
1Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
Insights
Childhood nonlymphocytic leukemia (ANLL) is rare but deadly. Advances in supportive care and aggressive therapies improve remission rates, but long-term survival remains low, highlighting the need for better treatments.
Area of Science:
- Pediatric Oncology
- Hematology
- Cancer Biology
Background:
- Childhood nonlymphocytic leukemia (ANLL) accounts for 25% of pediatric leukemia but a larger share of mortality.
- Despite improved supportive care and induction therapies, remission rates have improved, but long-term survival is still poor.
- Current treatment strategies lack methods to completely eradicate residual disease post-remission.
Purpose of the Study:
- To review recent advances in the treatment and understanding of childhood nonlymphocytic leukemia.
- To explore the potential of novel therapeutic approaches, including bone marrow transplantation and biologic studies.
- To highlight the significance of immunophenotype and karyotype studies in characterizing ANLL heterogeneity.
Main Methods:
- Review of recent literature on childhood nonlymphocytic leukemia.
- Analysis of advancements in supportive care, induction therapies, and post-remission disease control.
- Examination of biologic studies including surface immunophenotype, karyotype analysis, and oncogene research.
Main Results:
- Significant improvements in remission induction rates over the past two decades due to enhanced supportive care and aggressive therapies.
- Allogeneic bone marrow transplantation and autologous engraftment show promise for improved post-remission disease control.
- Biologic studies have elucidated ANLL heterogeneity, identified mixed myeloid/lymphoid leukemias, and revealed distinct karyotype subsets.
Conclusions:
- While remission rates have improved, long-term survival for ANLL remains a challenge, with only one in three patients surviving.
- Advances in bone marrow transplantation and biologic characterization offer hope for future therapeutic improvements.
- Further research into oncogenes and tailored therapies based on ANLL subsets may lead to better disease control and regulation of leukemic hematopoiesis.
Abstract:
Childhood nonlymphocytic leukemia comprises a minority (25%) of pediatric leukemia cases, yet contributes a significant proportion of overall leukemia mortality. Improvements in supportive care (antibiotics, antifungals, nutrition, and blood products) along with aggressive induction therapies have significantly improved remission induction rates over the past two decades. Ideal treatment to completely eliminate residual disease following remission is not yet known. In most series, only one out of three patients are long-term survivors of this disease. Recent advances in allogeneic bone marrow transplantation and improved techniques for autologous engraftment leave promise for significant improvements in postinduction disease control. Biologic studies of surface immunophenotype have contributed to our understanding of the heterogeneity of this family of disorders and allowed identification and characterization of leukemias of mixed myeloid/lymphoid lineage. Karyotype studies have identified important subsets of ANLL with distinctive clinical and biologic properties, for which tailored therapies someday may be developed. In addition, studies of oncogenes provide insight into regulation of leukemic hematopoiesis with potential of identifying future methods to regulate proliferation of the leukemic clone.